Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMT + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Rectal
01
Overview
FMT + tislelizumab is an investigational combination therapy being evaluated for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously failed treatment with immune checkpoint inhibitors. The therapy combines fecal microbiota transplantation (FMT), which involves the transfer of healthy donor stool to the patient's gastrointestinal tract to restore microbial diversity and modulate the systemic immune environment, with tislelizumab, a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By blocking the PD-1 pathway, tislelizumab prevents the suppression of T-cell activity, while FMT is hypothesized to overcome resistance mechanisms associated with an unfavorable gut microbiome. This clinical strategy, led by investigator Se-Hoon Lee, aims to restore the efficacy of immunotherapy in resistant NSCLC populations.
- Brand names
- Tevimbra
- Other names
- Fecal microbiota transplantation + tislelizumabFMT + BGB-A317
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on FMT + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMT + tislelizumab.